Effects of concurrent subchronic treatments with desmethylimipramine and propranolol on beta-adrenergic and serotonin2 receptors in rat brain
The effects of seven consecutive daily injections of desmethylimipramine (DMI 20 mg/kg) and propranolol (PRO 10 mg/kg) on 3H-dihydroalprenolol (3H-DHA) and 3H-ketanserin (3H-KET) binding in rat brain were examined. Analyses of saturation binding data using the iterative, nonlinear curve-fitting prog...
Gespeichert in:
| Veröffentlicht in: | Psychopharmacologia 1993, Vol.110 (1-2), p.110-114 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 114 |
|---|---|
| container_issue | 1-2 |
| container_start_page | 110 |
| container_title | Psychopharmacologia |
| container_volume | 110 |
| creator | MASON, G. A WALKER, C. H LITTLE, K. Y |
| description | The effects of seven consecutive daily injections of desmethylimipramine (DMI 20 mg/kg) and propranolol (PRO 10 mg/kg) on 3H-dihydroalprenolol (3H-DHA) and 3H-ketanserin (3H-KET) binding in rat brain were examined. Analyses of saturation binding data using the iterative, nonlinear curve-fitting program LIGAND revealed that PRO increased, while DMI reduced, 3H-DHA binding site density in cerebral cortex without altering receptor affinity, as previously reported. DMI reduced 3H-KET binding site density without changing affinity, and PRO produced the same effect. In cerebral cortex and probably in hippocampus and striatum, DMI and PRO administered together increased the density of 3H-DHA binding sites (beta-adrenergic receptors) and reduced their affinity. This combination of drugs reduced the density of 3H-KET binding sites (5-HT2 receptors) in cerebral cortex, but did not change their affinity. These findings indicate a need for additional studies on the interactions of DMI and PRO and related drugs because of implications for the treatment of depressed patients with cardiovascular disorders. |
| doi_str_mv | 10.1007/BF02246958 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_76310156</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>76310156</sourcerecordid><originalsourceid>FETCH-LOGICAL-c226t-848392af9c3fcbfeb5e292cb9bbe8e619ce0557c0e68f68aa2b0881671415e753</originalsourceid><addsrcrecordid>eNpFkMtqHDEQRYWJcSa2N9kbtDBZBDrRo_XopW38CAx4Y68bSVPKyHRLE0mNmY_IP0fGg1OboqoOh-Ii9JWSH5QQ9fP6jjDWy0HoI7SiPWcdI4p9QitCOO84Ffoz-lLKC2nV6_4EnSitiJZ6hf7eeg-uFpw8dim6JWeIFZfFum1OMThcM5g6t2XBr6Fu8QbKDHW7n8IcdtnMIQI2cYN3ObUxpilNOEVsoZrObJoN8u-meUMK5FSbNDKcwcGuplxwiDibim02IZ6hY2-mAueHfoqe726fbh669eP9r5urdecYk7XTveYDM35w3DvrwQpgA3N2sBY0SDo4IEIoR0BqL7UxzBKtqVS0pwKU4Kfo27u3Pf1ngVLHORQH02QipKWMSnJKqJAN_P4OupxKyeDHXQ6zyfuRkvEt-_F_9g2-OFgXO8PmAz2E3e6Xh7spzky-peVC-cB6wTmjiv8D7x-O4A</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>76310156</pqid></control><display><type>article</type><title>Effects of concurrent subchronic treatments with desmethylimipramine and propranolol on beta-adrenergic and serotonin2 receptors in rat brain</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>MASON, G. A ; WALKER, C. H ; LITTLE, K. Y</creator><creatorcontrib>MASON, G. A ; WALKER, C. H ; LITTLE, K. Y</creatorcontrib><description>The effects of seven consecutive daily injections of desmethylimipramine (DMI 20 mg/kg) and propranolol (PRO 10 mg/kg) on 3H-dihydroalprenolol (3H-DHA) and 3H-ketanserin (3H-KET) binding in rat brain were examined. Analyses of saturation binding data using the iterative, nonlinear curve-fitting program LIGAND revealed that PRO increased, while DMI reduced, 3H-DHA binding site density in cerebral cortex without altering receptor affinity, as previously reported. DMI reduced 3H-KET binding site density without changing affinity, and PRO produced the same effect. In cerebral cortex and probably in hippocampus and striatum, DMI and PRO administered together increased the density of 3H-DHA binding sites (beta-adrenergic receptors) and reduced their affinity. This combination of drugs reduced the density of 3H-KET binding sites (5-HT2 receptors) in cerebral cortex, but did not change their affinity. These findings indicate a need for additional studies on the interactions of DMI and PRO and related drugs because of implications for the treatment of depressed patients with cardiovascular disorders.</description><identifier>ISSN: 0033-3158</identifier><identifier>EISSN: 1432-2072</identifier><identifier>DOI: 10.1007/BF02246958</identifier><identifier>PMID: 7870868</identifier><identifier>CODEN: PSYPAG</identifier><language>eng</language><publisher>Berlin: Springer</publisher><subject>Animals ; Biological and medical sciences ; Brain Chemistry - drug effects ; Cerebral Cortex - drug effects ; Cerebral Cortex - metabolism ; Desipramine - pharmacology ; Dihydroalprenolol - pharmacokinetics ; Hippocampus - drug effects ; Hippocampus - metabolism ; In Vitro Techniques ; Ketanserin - metabolism ; Male ; Medical sciences ; Membranes - drug effects ; Membranes - metabolism ; Neostriatum - drug effects ; Neostriatum - metabolism ; Neuropharmacology ; Pharmacology. Drug treatments ; Propranolol - pharmacology ; Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease) ; Psychology. Psychoanalysis. Psychiatry ; Psychopharmacology ; Rats ; Rats, Sprague-Dawley ; Receptors, Adrenergic, beta - drug effects ; Receptors, Serotonin - drug effects</subject><ispartof>Psychopharmacologia, 1993, Vol.110 (1-2), p.110-114</ispartof><rights>1993 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c226t-848392af9c3fcbfeb5e292cb9bbe8e619ce0557c0e68f68aa2b0881671415e753</citedby><cites>FETCH-LOGICAL-c226t-848392af9c3fcbfeb5e292cb9bbe8e619ce0557c0e68f68aa2b0881671415e753</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,4023,27922,27923,27924</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=4533217$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/7870868$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>MASON, G. A</creatorcontrib><creatorcontrib>WALKER, C. H</creatorcontrib><creatorcontrib>LITTLE, K. Y</creatorcontrib><title>Effects of concurrent subchronic treatments with desmethylimipramine and propranolol on beta-adrenergic and serotonin2 receptors in rat brain</title><title>Psychopharmacologia</title><addtitle>Psychopharmacology (Berl)</addtitle><description>The effects of seven consecutive daily injections of desmethylimipramine (DMI 20 mg/kg) and propranolol (PRO 10 mg/kg) on 3H-dihydroalprenolol (3H-DHA) and 3H-ketanserin (3H-KET) binding in rat brain were examined. Analyses of saturation binding data using the iterative, nonlinear curve-fitting program LIGAND revealed that PRO increased, while DMI reduced, 3H-DHA binding site density in cerebral cortex without altering receptor affinity, as previously reported. DMI reduced 3H-KET binding site density without changing affinity, and PRO produced the same effect. In cerebral cortex and probably in hippocampus and striatum, DMI and PRO administered together increased the density of 3H-DHA binding sites (beta-adrenergic receptors) and reduced their affinity. This combination of drugs reduced the density of 3H-KET binding sites (5-HT2 receptors) in cerebral cortex, but did not change their affinity. These findings indicate a need for additional studies on the interactions of DMI and PRO and related drugs because of implications for the treatment of depressed patients with cardiovascular disorders.</description><subject>Animals</subject><subject>Biological and medical sciences</subject><subject>Brain Chemistry - drug effects</subject><subject>Cerebral Cortex - drug effects</subject><subject>Cerebral Cortex - metabolism</subject><subject>Desipramine - pharmacology</subject><subject>Dihydroalprenolol - pharmacokinetics</subject><subject>Hippocampus - drug effects</subject><subject>Hippocampus - metabolism</subject><subject>In Vitro Techniques</subject><subject>Ketanserin - metabolism</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Membranes - drug effects</subject><subject>Membranes - metabolism</subject><subject>Neostriatum - drug effects</subject><subject>Neostriatum - metabolism</subject><subject>Neuropharmacology</subject><subject>Pharmacology. Drug treatments</subject><subject>Propranolol - pharmacology</subject><subject>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopharmacology</subject><subject>Rats</subject><subject>Rats, Sprague-Dawley</subject><subject>Receptors, Adrenergic, beta - drug effects</subject><subject>Receptors, Serotonin - drug effects</subject><issn>0033-3158</issn><issn>1432-2072</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1993</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkMtqHDEQRYWJcSa2N9kbtDBZBDrRo_XopW38CAx4Y68bSVPKyHRLE0mNmY_IP0fGg1OboqoOh-Ii9JWSH5QQ9fP6jjDWy0HoI7SiPWcdI4p9QitCOO84Ffoz-lLKC2nV6_4EnSitiJZ6hf7eeg-uFpw8dim6JWeIFZfFum1OMThcM5g6t2XBr6Fu8QbKDHW7n8IcdtnMIQI2cYN3ObUxpilNOEVsoZrObJoN8u-meUMK5FSbNDKcwcGuplxwiDibim02IZ6hY2-mAueHfoqe726fbh669eP9r5urdecYk7XTveYDM35w3DvrwQpgA3N2sBY0SDo4IEIoR0BqL7UxzBKtqVS0pwKU4Kfo27u3Pf1ngVLHORQH02QipKWMSnJKqJAN_P4OupxKyeDHXQ6zyfuRkvEt-_F_9g2-OFgXO8PmAz2E3e6Xh7spzky-peVC-cB6wTmjiv8D7x-O4A</recordid><startdate>1993</startdate><enddate>1993</enddate><creator>MASON, G. A</creator><creator>WALKER, C. H</creator><creator>LITTLE, K. Y</creator><general>Springer</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>1993</creationdate><title>Effects of concurrent subchronic treatments with desmethylimipramine and propranolol on beta-adrenergic and serotonin2 receptors in rat brain</title><author>MASON, G. A ; WALKER, C. H ; LITTLE, K. Y</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c226t-848392af9c3fcbfeb5e292cb9bbe8e619ce0557c0e68f68aa2b0881671415e753</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1993</creationdate><topic>Animals</topic><topic>Biological and medical sciences</topic><topic>Brain Chemistry - drug effects</topic><topic>Cerebral Cortex - drug effects</topic><topic>Cerebral Cortex - metabolism</topic><topic>Desipramine - pharmacology</topic><topic>Dihydroalprenolol - pharmacokinetics</topic><topic>Hippocampus - drug effects</topic><topic>Hippocampus - metabolism</topic><topic>In Vitro Techniques</topic><topic>Ketanserin - metabolism</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Membranes - drug effects</topic><topic>Membranes - metabolism</topic><topic>Neostriatum - drug effects</topic><topic>Neostriatum - metabolism</topic><topic>Neuropharmacology</topic><topic>Pharmacology. Drug treatments</topic><topic>Propranolol - pharmacology</topic><topic>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopharmacology</topic><topic>Rats</topic><topic>Rats, Sprague-Dawley</topic><topic>Receptors, Adrenergic, beta - drug effects</topic><topic>Receptors, Serotonin - drug effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>MASON, G. A</creatorcontrib><creatorcontrib>WALKER, C. H</creatorcontrib><creatorcontrib>LITTLE, K. Y</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Psychopharmacologia</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>MASON, G. A</au><au>WALKER, C. H</au><au>LITTLE, K. Y</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effects of concurrent subchronic treatments with desmethylimipramine and propranolol on beta-adrenergic and serotonin2 receptors in rat brain</atitle><jtitle>Psychopharmacologia</jtitle><addtitle>Psychopharmacology (Berl)</addtitle><date>1993</date><risdate>1993</risdate><volume>110</volume><issue>1-2</issue><spage>110</spage><epage>114</epage><pages>110-114</pages><issn>0033-3158</issn><eissn>1432-2072</eissn><coden>PSYPAG</coden><abstract>The effects of seven consecutive daily injections of desmethylimipramine (DMI 20 mg/kg) and propranolol (PRO 10 mg/kg) on 3H-dihydroalprenolol (3H-DHA) and 3H-ketanserin (3H-KET) binding in rat brain were examined. Analyses of saturation binding data using the iterative, nonlinear curve-fitting program LIGAND revealed that PRO increased, while DMI reduced, 3H-DHA binding site density in cerebral cortex without altering receptor affinity, as previously reported. DMI reduced 3H-KET binding site density without changing affinity, and PRO produced the same effect. In cerebral cortex and probably in hippocampus and striatum, DMI and PRO administered together increased the density of 3H-DHA binding sites (beta-adrenergic receptors) and reduced their affinity. This combination of drugs reduced the density of 3H-KET binding sites (5-HT2 receptors) in cerebral cortex, but did not change their affinity. These findings indicate a need for additional studies on the interactions of DMI and PRO and related drugs because of implications for the treatment of depressed patients with cardiovascular disorders.</abstract><cop>Berlin</cop><pub>Springer</pub><pmid>7870868</pmid><doi>10.1007/BF02246958</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0033-3158 |
| ispartof | Psychopharmacologia, 1993, Vol.110 (1-2), p.110-114 |
| issn | 0033-3158 1432-2072 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_76310156 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Animals Biological and medical sciences Brain Chemistry - drug effects Cerebral Cortex - drug effects Cerebral Cortex - metabolism Desipramine - pharmacology Dihydroalprenolol - pharmacokinetics Hippocampus - drug effects Hippocampus - metabolism In Vitro Techniques Ketanserin - metabolism Male Medical sciences Membranes - drug effects Membranes - metabolism Neostriatum - drug effects Neostriatum - metabolism Neuropharmacology Pharmacology. Drug treatments Propranolol - pharmacology Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease) Psychology. Psychoanalysis. Psychiatry Psychopharmacology Rats Rats, Sprague-Dawley Receptors, Adrenergic, beta - drug effects Receptors, Serotonin - drug effects |
| title | Effects of concurrent subchronic treatments with desmethylimipramine and propranolol on beta-adrenergic and serotonin2 receptors in rat brain |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T07%3A06%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effects%20of%20concurrent%20subchronic%20treatments%20with%20desmethylimipramine%20and%20propranolol%20on%20beta-adrenergic%20and%20serotonin2%20receptors%20in%20rat%20brain&rft.jtitle=Psychopharmacologia&rft.au=MASON,%20G.%20A&rft.date=1993&rft.volume=110&rft.issue=1-2&rft.spage=110&rft.epage=114&rft.pages=110-114&rft.issn=0033-3158&rft.eissn=1432-2072&rft.coden=PSYPAG&rft_id=info:doi/10.1007/BF02246958&rft_dat=%3Cproquest_cross%3E76310156%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=76310156&rft_id=info:pmid/7870868&rfr_iscdi=true |